Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
EDP-323
ENANTA PHARMACEUTICALS INC
RSV Infection
3 trials -
EDP-494
ENANTA PHARMACEUTICALS INC
Hepatitis C
1 trial -
EDP-514
ENANTA PHARMACEUTICALS INC
Chronic HBV Infection
2 trials -
EDP-514
ENANTA PHARMACEUTICALS INC
Hepatitis B
1 trial -
EDP-721
ENANTA PHARMACEUTICALS INC
Chronic Hepatitis B Virus Infection
1 trial -
EDP-788
ENANTA PHARMACEUTICALS INC
Safety in Normal Volunteers
1 trial -
EDP-788
ENANTA PHARMACEUTICALS INC
Healthy
1 trial -
EDP-978
ENANTA PHARMACEUTICALS INC
Chronic Inducible Urticaria
1 trial -
EDP239
ENANTA PHARMACEUTICALS INC
Hepatitis C
1 trial -
ELX-02
Eloxx Pharmaceuticals
Impaired Renal Function
1 trial -
ELX-02
Eloxx Pharmaceuticals
Genetic Diseases
1 trial -
ENMD-2076
CASI Pharmaceuticals
Advanced Cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Multiple Myeloma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Relapsed or Refractory Hematological Malignancies
1 trial -
EP-104IAR
EUPRAXIA PHARMACEUTICALS INC.
Osteoarthritis, Knee
1 trial -
ESN364
Astellas Pharma Inc
Healthy Subjects
1 trial -
ET1402L1-ARTEMISβ’ T cells -IV
AEON Biopharma
Hepatocellular Carcinoma
1 trial -
EXS73565
RECURSION PHARMACEUTICALS, INC.
Relapsed or Refractory B-cell Malignancies
1 trial -
EXS74539
RECURSION PHARMACEUTICALS, INC.
Solid Tumor
1 trial -
Effect of Erythromycin on the absorption, metabolism and elimination of CHF6001 in healthy volunteers
Chiesi Farmaceutici S.p.A
This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.
1 trial -
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Merck Sharp and Dohme
Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).
1 trial -
Electroporation-Mediated Plasmid DNA Vaccine Therapy
INOVIO PHARMACEUTICALS, INC.
Chronic Hepatitis
1 trial -
Entinostat
Syndax Pharmaceuticals
Fallopian Tube Cancer
1 trial -
Entinostat
Syndax Pharmaceuticals
Renal Impairment
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources